ARYA Sciences Acquisition Corp IV (ARYD)
| Market Cap | 85.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 1.44M |
| Shares Out | 7.54M |
| EPS (ttm) | 0.09 |
| PE Ratio | 125.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58 |
| Open | 11.31 |
| Previous Close | 11.29 |
| Day's Range | 11.31 - 11.35 |
| 52-Week Range | 10.40 - 11.35 |
| Beta | -0.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ARYD
Arya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies
Combined Company expects to receive approximately $42 million from equity and convertible note investors at closing. LAGUNA HILLS, Calif.
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus' Gene Therapy Business Due to Market Conditions
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announc...